Flexion Therapeutics (FLXN) Stock Price, News & Analysis

Company Overview

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Key Stats

• Today's Range: $9.12 to $9.12
• 50-Day Range: $9.12 to $9.44
• 52-Week Range: $4.30 to $13.66
• Volume: N/A
• Average Volume: 1.18 million shs
• Market Capitalization: $458.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FLXN Stock Analysis - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings data on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), Lipocine (LPCN), Micron Technology (MU) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 5/12/2021
• Today: 7/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FLXN
• CIK: 1419600
• Web: www.flexiontherapeutics.com
• Phone: (781) 305-7777
• Fax: 781-202-3399
• Employees: 257
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.71 million
• Net Margins: -100.32%
• Pretax Margin: -100.32%
• Return on Equity: N/A
• Return on Assets: -44.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.38
• Quick Ratio: 4.05

Sales & Book Value

• Annual Sales: $85.55 million
• Price / Sales: 5.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.34) per share
• Price / Book: -26.82

Miscellaneous

• Outstanding Shares: 50,321,000
• Free Float: 45,727,000
• Market Cap: $458.93 million
• Optionable: Optionable
• Beta: 1.53